Clay Siegall is the co-founder and CEO of Seattle Genetics. He is a trained scientist who emphasizes on cancer therapies. Dr. Siegall created Seattle Genetics in 1998, in Bothell, Washington. Seattle Genetics was created with Dr. Siegall’s passion for helping patients through rigorous research and drug development practices.
1.Siegall has led the company to its current position as a leader in developing antibody-drug conjugates, or ADCs. In 2011, the FDA approved its first ADC product. Adcetris is now a global drug approved in more than 60 countries. In addition to Adcetris, Seattle Genetics is evolving a pipeline of ADCs for treating cancer.
Adcetris is Seattle Genetics’ lead program which is produced in collaboration with Takeda Pharmaceutical Company Limited. They are currently participating in a clinical development program to evaluate its potential to become the main form of treatment for treating advanced forms of cancer.
Their ADCs are created using Clay Siegall’s patented technology and includes more than 12 clinical programs. Their ADC technology is used by collaborators to work towards empowering antibodies to help improve treatment outcomes for cancer patients.
Under Siegall’s leadership, the drug company has entered into many licenses for its technology that have created more than $325 million. Across many programs, there are now more than 20 ADCs in development using Dr. Siegall’s technology. He has secured more than $1.2 billion in financing, which includes the company’s public offering in 2001.
Before founding Seattle Genetics, Clay Siegall worked for the Bristol-Myers Pharmaceutical Research Institute until 1997. Prior to that, he worked for both the National Cancer Institute and the National Institutes of Health until 1991.
2.Siegall currently serves on the Board of Directors at Mirna Therapeutics, Washington Roundtable, Ultragenyx Pharmaceutical, and Alder BioPharmaceuticals. He has received many awards, one of which was the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year.
In addition to his many work-related accomplishments, Clay Siegall has writted over 70 publications and currently holds 15 patents. His education includes a Bachelor’s Degree in Zoology from the University of Maryland and a Ph.D. in Genetics from the George Washington University.